Bayer has emerged victorious in a Roundup weedkiller cancer trial, putting an end to a troubling five-trial losing streak for the company, Reuters reported.<o:p></o:p>

The verdict was delivered on Friday by a jury in San Benito County, California Superior Court, marking a crucial win for Bayer in trials related to claims of cancer development due to Roundup exposure. <o:p></o:p>

The company, in a statement, emphasised that the verdict aligns with the evidence, asserting that "Roundup does not cause cancer and is not responsible for the plaintiff's illness." <o:p></o:p>

The plaintiff, Bruce Jones, had alleged that Roundup led to his non-Hodgkin lymphoma.<o:p></o:p>

The victory is a pivotal moment for Bayer, which had faced mounting legal challenges with around 165,000 claims asserting personal injuries attributed to Roundup. The weedkiller became part of Bayer's portfolio through its acquisition of U.S. agrochemical company Monsanto for $63 billion in 2018. <o:p></o:p>

Prior to the recent losses, Bayer had a track record of winning nine consecutive trials. With the latest win, the company has secured victory in 10 out of the last 15 trials. <o:p></o:p>

More cases are scheduled for trial in the coming year.<o:p></o:p>

The legal battles have had financial implications for Bayer, with recent losses resulting in verdicts totalling over $2 billion. Investors had expressed concerns over the company's legal strategy, prompting Bayer to reaffirm its commitment to fighting the Roundup cases in court rather than opting for settlements. <o:p></o:p>

Bayer is currently appealing the unfavourable verdicts, including punitive damages that exceed U.S. Supreme Court guidance. The outcome of these appeals will likely have more financial consequences for Bayer. <o:p></o:p>

The company however, has expressed "no appetite to write humongous checks" to settle the claims.<o:p></o:p>

While Bayer settled most Roundup cases in 2020 for up to $9.6 billion, the agreement did not cover future cases, leaving over 50,000 claims pending. <o:p></o:p>

The recent victory in the Roundup cancer trial provides a glimmer of hope for Bayer, but the legal battles are far from over.<o:p></o:p>

(With inputs from Reuters)<o:p></o:p>

WATCH WION LIVE HERE

<iframe allow="accelerometer; autoplay; encrypted-media; gyroscope; picture-in-picture" allowfullscreen="" frameborder="0" height="350" src="https://www.wionews.com/live-tv/embed?autoplay=1&amp;mute=1" width="100%"></iframe>

Bayer has emerged victorious in a Roundup weedkiller cancer trial, putting an end to a troubling five-trial losing streak for the company, Reuters reported. The verdict was delivered on Friday by a jury in San Benito County, California Superior Court, marking a crucial win for Bayer in trials related to claims of cancer development due to Roundup exposure.

Bayer has emerged victorious in a Roundup weedkiller cancer trial, putting an end to a troubling five-trial losing streak for the company, Reuters reported. The verdict was delivered on Friday by a jury in San Benito County, California Superior Court, marking a crucial win for Bayer in trials related to claims of cancer development due to Roundup exposure. The company, in a statement, emphasised that the verdict aligns with the evidence, asserting that "Roundup does not cause cancer and is not responsible for the plaintiff's illness." The plaintiff, Bruce Jones, had alleged that Roundup led to his non-Hodgkin lymphoma. The victory is a pivotal moment for Bayer, which had faced mounting legal challenges with around 165,000 claims asserting personal injuries attributed to Roundup. The weedkiller became part of Bayer's portfolio through its acquisition of U.S. agrochemical company Monsanto for $63 billion in 2018. Prior to the recent losses, Bayer had a track record of winning nine consecutive trials. With the latest win, the company has secured victory in 10 out of the last 15 trials. More cases are scheduled for trial in the coming year. The legal battles have had financial implications for Bayer, with recent losses resulting in verdicts totalling over $2 billion. Investors had expressed concerns over the company's legal strategy, prompting Bayer to reaffirm its commitment to fighting the Roundup cases in court rather than opting for settlements. Bayer is currently appealing the unfavourable verdicts, including punitive damages that exceed U.S. Supreme Court guidance. The outcome of these appeals will likely have more financial consequences for Bayer. The company however, has expressed "no appetite to write humongous checks" to settle the claims. While Bayer settled most Roundup cases in 2020 for up to $9.6 billion, the agreement did not cover future cases, leaving over 50,000 claims pending. The recent victory in the Roundup cancer trial provides a glimmer of hope for Bayer, but the legal battles are far from over. (With inputs from Reuters) WATCH WION LIVE HERE

Bayer breaks losing streak with victory in roundup cancer trial

German pharmaceutical firms Bayer and CureVac said Thursday that they have joined forces in the development of CureVac's Covid-19 vaccine candidate.&nbsp;

Under the deal, CureVac will be able to tap Bayer's expertise and established infrastructure, according to a joint statement.

The agreement "will help us make our vaccine candidate even more rapidly available to as many people as possible," CureVac chief executive Franz-Werner Haas said.

Also, Germany's Bayer will provide access to international pharmaceutical markets as well as its global supply chain and distribution network, the tabloid newspaper reported in an excerpt made available to Reuters ahead of publication.

CureVac last month started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.

German pharmaceutical firms Bayer and CureVac said Thursday that they have joined forces in the development of CureVac's Covid-19 vaccine candidate. Under the deal, CureVac will be able to tap Bayer's expertise and established infrastructure, according to a joint statement.

German pharmaceutical firms Bayer and CureVac said Thursday that they have joined forces in the development of CureVac's Covid-19 vaccine candidate. Under the deal, CureVac will be able to tap Bayer's expertise and established infrastructure, according to a joint statement. The agreement "will help us make our vaccine candidate even more rapidly available to as many people as possible," CureVac chief executive Franz-Werner Haas said. Also, Germany's Bayer will provide access to international pharmaceutical markets as well as its global supply chain and distribution network, the tabloid newspaper reported in an excerpt made available to Reuters ahead of publication. CureVac last month started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna to lead the development race.

Bayer, CureVac to 'join forces' on Covid-19 vaccine candidate

German chemical giants <a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer </a>and BASF will appeal against the fine of $265 million imposed upon them by a US&nbsp;court over a weedkiller produced by them.

A US jury had&nbsp;awarded $265 million to a Missouri farmer who blamed dicamba&nbsp;herbicide from chemical giants&nbsp;for destroying his peach orchards.

It was&nbsp;the first ruling in some 140 US cases against dicamba, a herbicide blamed for extensive crop damage.

Also read:&nbsp;<a href="https://www.wionews.com/world/monsanto-owners-call-weed-killer-safe-after-jury-orders-big-payout-158587">Monsanto owners call weed killer 'safe' after jury orders big payout</a>

<a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer </a>says its herbicides pose no unreasonable risk if used correctly.

BASF said it would "use all available legal resources" to fight Saturday's ruling by a federal district court in Cape Girardeau, Missouri.

<a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer </a>insists that <a href="https://www.wionews.com/world/monsanto-owners-call-weed-killer-safe-after-jury-orders-big-payout-158587">Monsanto </a>herbicides are safe and "valuable tools for growers". The herbicides "do not pose any unreasonable risk of off-target movement when used according to label directions", the firm says.

The company&nbsp;had taken over the US agrochemical giant Monsanto for $63bn in 2018.

Also read:&nbsp;<a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer takes over Monsanto with a $128 per share offer: Sources</a>

After this takeover, it introduced seeds that can resist the weed-killer due to which use of the chemicals increased.

But the product has been blamed for polluting around four percent of US soybean fields in 2017.

A common complaint is that the herbicide spreads to nearby areas.

The company sells dicamba-based herbicide and a similar, much-criticised product, Roundup.

US lawsuits against <a href="https://www.wionews.com/world/monsanto-owners-call-weed-killer-safe-after-jury-orders-big-payout-158587">Monsanto's </a>weed killers may cost <a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer </a>billions of dollars in damages.

The fight over dicamba comes in the wake of a case in which&nbsp;<a href="https://www.wionews.com/business-economy/bayer-takes-over-monsanto-with-a-128-per-share-offer-sources-6323">Bayer&nbsp;</a>was ordered by a California jury to pay $290 million for failing to warn a dying groundskeeper that Roundup might cause cancer.

German chemical giants Bayer and BASF will appeal against the fine of $265 million imposed upon them by a US court over a weedkiller produced by them. A US jury had awarded $265 million to a Missouri farmer who blamed dicamba herbicide from chemical giants for destroying his peach orchards.

German chemical giants Bayer and BASF will appeal against the fine of $265 million imposed upon them by a US court over a weedkiller produced by them. A US jury had awarded $265 million to a Missouri farmer who blamed dicamba herbicide from chemical giants for destroying his peach orchards. It was the first ruling in some 140 US cases against dicamba, a herbicide blamed for extensive crop damage. Also read: Monsanto owners call weed killer 'safe' after jury orders big payout Bayer says its herbicides pose no unreasonable risk if used correctly. BASF said it would "use all available legal resources" to fight Saturday's ruling by a federal district court in Cape Girardeau, Missouri. Bayer insists that Monsanto herbicides are safe and "valuable tools for growers". The herbicides "do not pose any unreasonable risk of off-target movement when used according to label directions", the firm says. The company had taken over the US agrochemical giant Monsanto for $63bn in 2018. Also read: Bayer takes over Monsanto with a $128 per share offer: Sources After this takeover, it introduced seeds that can resist the weed-killer due to which use of the chemicals increased. But the product has been blamed for polluting around four percent of US soybean fields in 2017. A common complaint is that the herbicide spreads to nearby areas. The company sells dicamba-based herbicide and a similar, much-criticised product, Roundup. US lawsuits against Monsanto's weed killers may cost Bayer billions of dollars in damages. The fight over dicamba comes in the wake of a case in which Bayer was ordered by a California jury to pay $290 million for failing to warn a dying groundskeeper that Roundup might cause cancer.

German chemical firms to appeal against $265mn fine imposed by US court

Brewing <a href="https://www.wionews.com/business-economy/asia-stocks-higher-ahead-of-fed-pound-pressured-by-fresh-brexit-pain-239341">no-deal Brexit</a> worries sent the pound sinking towards a two-year low versus the euro and roughed up Irish bonds on Tuesday, while stock markets wilted before what is expected to be the first cut in rates since the financial crisis.

Europe's markets suffered a stormy start as the pound followed its worst day of the year with another 0.5% swoon against all the major currencies.

A blizzard of fiery talk on Monday that included the new UK Prime Minister Boris Johnson called his predecessor's Brexit plans dead and its new foreign minister labelling the European Union "stubborn" kept the slide intact.

<a href="https://www.wionews.com/world/uk-plays-brexit-hardball-with-stubborn-european-union-pound-falls-to-a-two-year-low-239235">Sterling fell</a> as far as $1.2120, which was its lowest against the dollar since March 2017, and to 91.85 pence per euro, the weakest since September 2017.

Options markets were pointing to more pain too. Three-month implied volatility, a contract that expires just before the October&nbsp;31 Brexit deadline, jumped to over 11 vols, the highest since before March 29, the original date for Britain to leave the European Union.

"The pound is in a very precarious state, it is as simple as that," said TD Securities' European head of currency strategy Ned Rumpeltin.

"We are now in a different regime," he said, referring to Johnson's explicit agenda of taking Britain out of the EU, whether or not transitional trading agreements are in place.

It was not just sterling reeling either.

Irish government bond yield spreads over Germany hit their widest levels in over a month at 24 basis points, on worries about the damage a no-deal Brexit would do to Ireland's economy.

Other eurozone government bond yields were holding near recent lows ahead of the Federal Reserve meeting which is expected to deliver a 25 basis point rate cut on Wednesday and potentially signal more on the way.

Germany's 10-year government bond yield was hovering near the minus 0.40% mark.

European shares slipped as grim forecasts from German chemicals and drugs giant Bayer and airline Lufthansa soured sentiment, although the weakness of the pound kept London's blue-chip FTSE index just about out of the red.

With concerns about global growth still bubbling among investors, a GfK survey also showed German consumer morale worsening for the third month in a row heading into August as trade disputes bit in Europe's biggest exporter.

"Most markets are down this morning," said Simona Gambarini, a markets economist at Capital Economics. "The S&amp;P closed lower yesterday. We have a few data releases regarding the eurozone that could push equity prices down but I think everyone is waiting for the Fed meeting."

Aussie Gold

Asia had been a bit more positive overnight.

Japan's Nikkei rose 0.4%, showing a limited reaction to the Bank of Japan's widely anticipated decision to stand pat on monetary policy. Shanghai rose 0.3% and Hong Kong's Hang Seng edged up 0.2%.

Australian stocks stole the glory again though with another record high, as buoyant mining shares added to tech-driven gains the previous day.

The BOJ added that it would ease policy again "without hesitation" if the economy loses momentum for achieving the central bank's 2% inflation target.

Also drawing some attention were US-China trade negotiations which begin in Shanghai on Tuesday, although expectations for progress during the two-day meeting are low with the markets hoping the two sides can at least detail commitments for "goodwill" gestures.

Among commodities, crude oil prices extended the previous day's gains, with the Fed's expected easing fuelling optimism that it would boost the economy and fuel demand in the world's biggest oil consumer.

US crude futures were up 0.65% at $57.24 per barrel and Brent crude added 0.6% to $64.09. Gold was down 0.1% at $1,425 per ounce.

Brewing no-deal Brexit worries sent the pound sinking towards a two-year low versus the euro and roughed up Irish bonds on Tuesday, while stock markets wilted before what is expected to be the first cut in rates since the financial crisis.

Brewing no-deal Brexit worries sent the pound sinking towards a two-year low versus the euro and roughed up Irish bonds on Tuesday, while stock markets wilted before what is expected to be the first cut in rates since the financial crisis. Europe's markets suffered a stormy start as the pound followed its worst day of the year with another 0.5% swoon against all the major currencies. A blizzard of fiery talk on Monday that included the new UK Prime Minister Boris Johnson called his predecessor's Brexit plans dead and its new foreign minister labelling the European Union "stubborn" kept the slide intact. Sterling fell as far as $1.2120, which was its lowest against the dollar since March 2017, and to 91.85 pence per euro, the weakest since September 2017. Options markets were pointing to more pain too. Three-month implied volatility, a contract that expires just before the October 31 Brexit deadline, jumped to over 11 vols, the highest since before March 29, the original date for Britain to leave the European Union. "The pound is in a very precarious state, it is as simple as that," said TD Securities' European head of currency strategy Ned Rumpeltin. "We are now in a different regime," he said, referring to Johnson's explicit agenda of taking Britain out of the EU, whether or not transitional trading agreements are in place. It was not just sterling reeling either. Irish government bond yield spreads over Germany hit their widest levels in over a month at 24 basis points, on worries about the damage a no-deal Brexit would do to Ireland's economy. Other eurozone government bond yields were holding near recent lows ahead of the Federal Reserve meeting which is expected to deliver a 25 basis point rate cut on Wednesday and potentially signal more on the way. Germany's 10-year government bond yield was hovering near the minus 0.40% mark. European shares slipped as grim forecasts from German chemicals and drugs giant Bayer and airline Lufthansa soured sentiment, although the weakness of the pound kept London's blue-chip FTSE index just about out of the red. With concerns about global growth still bubbling among investors, a GfK survey also showed German consumer morale worsening for the third month in a row heading into August as trade disputes bit in Europe's biggest exporter. "Most markets are down this morning," said Simona Gambarini, a markets economist at Capital Economics. "The S&P closed lower yesterday. We have a few data releases regarding the eurozone that could push equity prices down but I think everyone is waiting for the Fed meeting." Aussie Gold Asia had been a bit more positive overnight. Japan's Nikkei rose 0.4%, showing a limited reaction to the Bank of Japan's widely anticipated decision to stand pat on monetary policy. Shanghai rose 0.3% and Hong Kong's Hang Seng edged up 0.2%. Australian stocks stole the glory again though with another record high, as buoyant mining shares added to tech-driven gains the previous day. The BOJ added that it would ease policy again "without hesitation" if the economy loses momentum for achieving the central bank's 2% inflation target. Also drawing some attention were US-China trade negotiations which begin in Shanghai on Tuesday, although expectations for progress during the two-day meeting are low with the markets hoping the two sides can at least detail commitments for "goodwill" gestures. Among commodities, crude oil prices extended the previous day's gains, with the Fed's expected easing fuelling optimism that it would boost the economy and fuel demand in the world's biggest oil consumer. US crude futures were up 0.65% at $57.24 per barrel and Brent crude added 0.6% to $64.09. Gold was down 0.1% at $1,425 per ounce.

Stormy sterling sinks again, stocks wilt before Fed

US agriculture company Monsanto agreed to a takeover from Bayer with a USD 128 per share offer, Reuters reported on Wednesday. 
 
The companies have agreed on a break-up fee of USD 2 billion, a person familiar with the matter told Reuters. The deal is expected to be closed by the end of 2017, the source said. 
 
The new offer would value Monsanto at USD 56.5 billion. 
 
Bayer chief executive Werner Baumann first made his bid for Monsanto four months ago. The German pharmaceutical and chemical group had initially offered USD 122 per share in May. Monsanto rejected the offer as &quot;incomplete and financially inadequate&quot;. 
 
The merger of the two would create a new global leader in agrochemical businesses. 
 
As part of its latest proposal, Bayer is also offering to double, to USD 3 billion, the compensation it would have to pay to Monsanto if the deal is stopped by competition regulators, Rheinische Post said. 
 
&ldquo;We see the Bayer-Monsanto deal as close to an end,&rdquo; analysts at Germany&rsquo;s DZ Bank wrote in a note Wednesday morning, The Wall Street Journal reported. &ldquo;We don&#39;t like the transaction because we think that Bayer is overpaying significantly,&rdquo; the analysts said. 
 
(WION with inputs from agencies)

Bayer chief executive had made his first bid for Monsanto, which will now be valued at $56.5 billion, four months ago

US agriculture company Monsanto agreed to a takeover from Bayer with a USD 128 per share offer, Reuters reported on Wednesday. The companies have agreed on a break-up fee of USD 2 billion, a person familiar with the matter told Reuters. The deal is expected to be closed by the end of 2017, the source said. The new offer would value Monsanto at USD 56.5 billion. Bayer chief executive Werner Baumann first made his bid for Monsanto four months ago. The German pharmaceutical and chemical group had initially offered USD 122 per share in May. Monsanto rejected the offer as "incomplete and financially inadequate". The merger of the two would create a new global leader in agrochemical businesses. As part of its latest proposal, Bayer is also offering to double, to USD 3 billion, the compensation it would have to pay to Monsanto if the deal is stopped by competition regulators, Rheinische Post said. “We see the Bayer-Monsanto deal as close to an end,” analysts at Germany’s DZ Bank wrote in a note Wednesday morning, The Wall Street Journal reported. “We don't like the transaction because we think that Bayer is overpaying significantly,” the analysts said. (WION with inputs from agencies)

Bayer takes over Monsanto with a $128 per share offer: Sources

bayer

Bayer, News on Bayer, stories on Bayer, articles on Bayer, Bayer stories at Wion, Bayer news, Bayer latest news